Skip Ribbon Commands
Skip to main content
Sign In

25008 ADAMTS13 Evaluation, Rapid

ADAMTS13 Evaluation, Rapid
Test Code: ADAMT13
Synonyms/Keywords
ADAMTS Activity
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Plasma​ Citrated Blue Top Tube (BTT)​ Two 0.75 mL  aliquots​
Two 0.75 mL 
aliquots​
 0.5 mL​
Collection Processing Instructions

​One 0.75 mL citrated Blue Top Tube (BTT) plasma aliquot.
If more than one coagulation test is ordered, a separate aliquot is needed for each test.
-Collect in Citrated Blue Top Tube (BTT)
-Citrate anticoagulant must be adjusted for HCT >55%
-Tube must be at least 90% full
-Invert completely 3-4 times (without shaking) to mix
-See (Preparation of Platelet Poor Plasma)

Plasma must be removed from cells and frozen within 2 hours.

Specimen Stability Information
Specimen Type Temperature Time
​Plasma ​Frozen ​6 months
Rejection Criteria
Clotted or Hemolyzed
​Contamination with IV or Hickman Line fluids
​Specimens that thaw during storage or transport
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Marshfield ​Monday through Friday 6-7 hours ELISA
Test Information

This test should be regarded as 'Research Use Only'. The performance characteristics were determined by Marshfield Labs in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. It may not be covered by insurance and providers need to inform all patients of this prior to ordering. 

For Medicare patients, an Advanced Beneficiary notice (ABN) is required; for Medicaid patients, a Noncovered Services Waiver is required, and for commercial payers, prior authorization should be obtained.

ADAMTS13 Activity is always performed. If activity is below the stated reference range, the inhibitor may be performed following internal pathologist review. ADAMTS13 is a plasma protein that regulates the size of the von Willebrand factor. Absent or low ADAMTS13 activity allows formation of platelet microthrombi, which in turn obstruct arterioles and capillaries, generating the clinical sequelae of Thrombotic thrombocytopenic purpura (TTP). ADAMTS13 deficiency can be congenital or acquired. In idiopathic TTP, acquired deficiency of ADAMTS13 is attributed to the presence of autoantibody, which may either inhibit ADAMTS13 function (which is reported as an inhibitor) or may cause clearance of circulation ADAMTS13. While patients with congenital deficiency of ADAMTS13 respond to simple plasma infusion therapy, patients with idiopathic TTP usually require therapeutic plasma exchange to achieve clinical remission.
The rapid ADAMTS13 test (Testcode ADAMT13) is recommended when the diagnosis of thrombotic thrombocytopenia purpura (TTP) is being considered and therapeutic decisions hang in the balance (e.g. placement of a central line and initiation of plasma exchange). Same day turn-around-time (TAT) is necessary and the rapid ADAMTS13 in-house assay performed by Marshfield Laboratories is appropriate.
For follow-up of a patient with TTP to assess recurrence risk, a more delayed TAT is acceptable, and the less expensive sendout ADAMTS13 test (Testcode ADAMTSO) is appropriate.
Consultation with a hematologist, hematopathologist, or coagulation specialist is advised for unusual clinical situations.

Reference Range Information
Performing Location Reference Range
​Marshfield

ADAMTS Activity: 40 - 130% Normal Activity ​

Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​85397
Classification

This test should be regarded as 'Research Use Only'. The performance characteristics were determined by Marshfield Labs in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. It may not be covered by insurance and providers need to inform all patients of this prior to ordering. 

For Medicare patients, an Advanced Beneficiary notice (ABN) is required; for Medicaid patients, a Noncovered Services Waiver is required, and for commercial payers, prior authorization should be obtained.

Synonyms/Keywords
ADAMTS Activity
Ordering Applications
Ordering Application Description
​Centricity ​ADAMTS13 Evaluation, Rapid
​Cerner ​None
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Plasma​ Citrated Blue Top Tube (BTT)​ Two 0.75 mL  aliquots​
Two 0.75 mL 
aliquots​
 0.5 mL​
Collection Processing

​One 0.75 mL citrated Blue Top Tube (BTT) plasma aliquot.
If more than one coagulation test is ordered, a separate aliquot is needed for each test.
-Collect in Citrated Blue Top Tube (BTT)
-Citrate anticoagulant must be adjusted for HCT >55%
-Tube must be at least 90% full
-Invert completely 3-4 times (without shaking) to mix
-See (Preparation of Platelet Poor Plasma)

Plasma must be removed from cells and frozen within 2 hours.

Specimen Stability Information
Specimen Type Temperature Time
​Plasma ​Frozen ​6 months
Rejection Criteria
Clotted or Hemolyzed
​Contamination with IV or Hickman Line fluids
​Specimens that thaw during storage or transport
Reference Range Information
Performing Location Reference Range
​Marshfield

ADAMTS Activity: 40 - 130% Normal Activity ​

For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Marshfield ​Monday through Friday 6-7 hours ELISA
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​85397
Classification

This test should be regarded as 'Research Use Only'. The performance characteristics were determined by Marshfield Labs in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. It may not be covered by insurance and providers need to inform all patients of this prior to ordering. 

For Medicare patients, an Advanced Beneficiary notice (ABN) is required; for Medicaid patients, a Noncovered Services Waiver is required, and for commercial payers, prior authorization should be obtained.

For most current information refer to the Marshfield Laboratory online reference manual.